ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION

INTRODUCTION: Isocitrate dehydrogenase 1/2 (IDH1/2) mutations occur in >70% of low-grade gliomas (LGG) and lead to an altered metabolic state associated with production of D-2-hydroxyglutarate (2-HG), resulting in genetic/epigenetic dysregulation and oncogenesis. AG-120 is a potent oral inhibitor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Mellinghoff, Ingo K, Touat, Mehdi, Maher, Elizabeth, De La Fuente, Macarena, Cloughesy, Timothy F, Holdhoff, Matthias, Cote, Gregory M, Burris, Howard, Janku, Filip, Huang, Ray, Young, Robert J, Ellingson, Benjamin, Nimkar, Tara, Jiang, Liewen, Ishii, Yuko, Choe, Sung, Fan, Bin, Steelman, Lori, Yen, Katharine, Bowden, Chris, Pandya, Susan, Wen, Patrick Y
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691984/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.037
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak